Chronic Kidney Disease

The AJMC® Chronic Kidney Disease compendium is a comprehensive resource for clinical news and expert insights on the condition and treatment of loss of kidney function.

Latest News

Viet Le, PA-C, Intermountain Health
Fostering Interdisciplinary Communication: How Cardio-Renal-Metabolic Care Models Optimize Care Delivery

October 19th 2024

Viet Le, PA-C, Intermountain Health, gives insights into the benefits cardio-renal-metabolic care models provide for patients in need.

Navdeep Tangri, MD, PhD, FRCP
Population Health Strategies Are Vital for Tackling, Improving CKD Care

October 18th 2024

Value-based care calls for long-term thinking about sustained benefit | image credit: momius - stock.adobe.com
Long-Term Benefits Show the Value of Upfront Investments in Value-Based Care

October 17th 2024

AJMC
Identifying Chronic Kidney Disease Stage 3 With Excess Disease Burden

June 24th 2024

AJMC
Defragmentation of Care in Complex Patients With ESKD Improves Clinical Outcomes

May 13th 2024

Population Health Management of Chronic Kidney Disease (CKD)

An expert panel discusses chronic kidney disease (CKD), its impact on cardiovascular disease, and the methods of treatment used on the patient populations.

Panel members

More News

Future Management of Anemia in CKD
August 4th 2020

Future Management of Anemia in CKD

Future Treatment of Anemia in CKD: Impact of HIF Stabilizers
August 4th 2020

Future Treatment of Anemia in CKD: Impact of HIF Stabilizers

Anemia in CKD: HIF Stabilizers in Clinical Trials
August 4th 2020

Anemia in CKD: HIF Stabilizers in Clinical Trials

Payer Perspective of HIF Stabilizers for Anemia in CKD
August 4th 2020

Payer Perspective of HIF Stabilizers for Anemia in CKD

HIF Stabilizers: Management of Anemia in CKD
August 4th 2020

HIF Stabilizers: Management of Anemia in CKD

HIMALAYAS Trial: Long-Term Cardiovascular Safety Data
August 4th 2020

HIMALAYAS Trial: Long-Term Cardiovascular Safety Data

HIF Stabilizers for Anemia in CKD: Phase 3 Trials
August 4th 2020

HIF Stabilizers for Anemia in CKD: Phase 3 Trials

Treatment of Anemia in CKD During COVID-19
August 4th 2020

Treatment of Anemia in CKD During COVID-19

Economic Burden of Anemia in CKD
August 4th 2020

Economic Burden of Anemia in CKD

Anemia in CKD: CHOIR and TREAT Trials
August 4th 2020

Anemia in CKD: CHOIR and TREAT Trials

Standard of Care: Therapeutic Options for Anemia in CKD
August 4th 2020

Standard of Care: Therapeutic Options for Anemia in CKD

Treatment of Anemia in CKD
August 4th 2020

Treatment of Anemia in CKD

Payer Perspective of Anemia in CKD
August 4th 2020

Payer Perspective of Anemia in CKD

Role of Anemia in CKD
August 4th 2020

Role of Anemia in CKD

Overview of Chronic Kidney Disease
August 4th 2020

Overview of Chronic Kidney Disease

FDA Grants Orphan Drug Status to Regulus Therapeutics' Treatment for Common Type of PKD
July 30th 2020

FDA Grants Orphan Drug Status to Regulus Therapeutics' Treatment for Common Type of PKD

Mary Caffrey
Although the name suggests the disease affects only the kidneys, development of fluid-filled cysts can spread to the liver, the pancreas, and other organs. While a healthy kidney is about the size of a fist, a kidney filled with cysts from polycystic kidney disease (PKD) can grow to be about the size of a football weigh up to 30 pounds
Dapagliflozin Meets All Targets in Patients With Chronic Kidney Disease, With and Without Diabetes
July 28th 2020

Dapagliflozin Meets All Targets in Patients With Chronic Kidney Disease, With and Without Diabetes

Mary Caffrey
Data from DAPA-CKD show that the trial met all its primary and secondary end points for patients with chronic kidney disease, with and without type 2 diabetes. The announcement comes after a data monitoring committee halted the trial in March 2020 when it found the evidence of efficacy was overwhelming.
When Should Renal Replacement Therapy Start After Acute Kidney Injury?
July 25th 2020

When Should Renal Replacement Therapy Start After Acute Kidney Injury?

Mary Caffrey
Just when renal replacement therapy should start after acute kidney injury has been debated.
National Kidney Foundation, NCQA Announce Measure to Boost Testing in Patients With Diabetes
July 24th 2020

National Kidney Foundation, NCQA Announce Measure to Boost Testing in Patients With Diabetes

AJMC Staff
While clinical guidelines call for those with diabetes to be tested regularly for kidney disease, less than 50% of these patients are tested once a year, according to the National Kidney Foundation.
Site Logo
July 16th 2020

Racial, Socioeconomic Disparities Continue in Prevalence of CKD Over Time

Allison Inserro
The authors said the results show a need to develop more targeted interventions for populations at risk of chronic kidney disease (CKD).
Site Logo
July 15th 2020

Profiles of COVID-19 Patients: A Study of Private Health Care Claims

Robin Gelburd, JD
Researchers Find Alternatives for Acetaminophen Without Liver, Kidney Effects
July 10th 2020

Researchers Find Alternatives for Acetaminophen Without Liver, Kidney Effects

Mary Caffrey
The coronavirus disease 2019 pandemic presents a new challenge: patients have severe flu-like symptoms, but the virus can also cause renal failure. Doctors and patients need analgesics that go easy on the liver and kidneys but are not addictive, and this week researchers at LSU Health New Orleans Neuroscience Center of Excellence announced they have discovered a new class of drugs that can do the job.
This Week in Managed Care: July 10, 2020
July 10th 2020

This Week in Managed Care: July 10, 2020

This week, the top managed care news included CMS planning to pay more for at-home dialysis equipment; ACR supports continued use of telemedicine after the COVID-19 pandemic passes; AJMC®’s coverage of AIDS 2020, the 23rd International AIDS Conference.
CMS Seeks Incentives for At-Home Dialysis in Wake of COVID-19
July 7th 2020

CMS Seeks Incentives for At-Home Dialysis in Wake of COVID-19

Mary Caffrey
End-stage renal disease has long been one of the most expensive and debilitating conditions that affects Medicare beneficiaries. Not only does dialysis cost $90,000 a year—those awaiting a kidney transplant automatically qualify for Medicare—but the need to travel to a dialysis center multiple times a week disrupts employment and home life.
Frequently Prescribed Allopurinol No Better Than Placebo for CKD in Head-to-Head Trial
July 4th 2020

Frequently Prescribed Allopurinol No Better Than Placebo for CKD in Head-to-Head Trial

Mary Caffrey
Results from the University of New South Wales appeared in the New England Journal of Medicine. The co-lead investigator said the results show the need for more treatment options in chronic kidney disease.
Study of Fat Cells May Hint at Target in Chronic Renal Failure
July 1st 2020

Study of Fat Cells May Hint at Target in Chronic Renal Failure

AJMC Staff
Previously, fat cells, called adipocytes, were not known to have a role in renal failure-associated cardiomyopathy.
Dana-Farber Scientists Find Biomarker for Kidney Cancer
June 25th 2020

Dana-Farber Scientists Find Biomarker for Kidney Cancer

Mary Caffrey
A coauthor of the study said that if the noninvasive test was used more widely, before kidney cancers have spread, fewer people would die from the disease.
Kidney Failure Due to Acute Injury Deadlier Than Diabetes, Data Show
June 23rd 2020

Kidney Failure Due to Acute Injury Deadlier Than Diabetes, Data Show

Mary Caffrey
Acute kidney injury is a sudden onset of kidney damage that causes waste products to build up in the body. These episodes have become more common during the coronavirus disease 2019 pandemic, causing kidney failure in some previously healthy patients who had no prior history of renal problems.
Differences in Basal Insulins for Patients in Renal Failure
June 20th 2020

Differences in Basal Insulins for Patients in Renal Failure

Mary Caffrey
In a poster titled “Basal Insulins in Advanced Renal Failure: Time for a Paradigm Shift,” authors compared the safety and efficacy of insulin degludec (Tresiba) with insulin glargine 100U (Lantus) among patients with stage 3 and stage 4 chronic kidney disease (CKD).
Lexicon's Sotagliflozin Meets Mark in T2D With Moderate Renal Impairment, but Misses on Sicker Patients
June 19th 2020

Lexicon's Sotagliflozin Meets Mark in T2D With Moderate Renal Impairment, but Misses on Sicker Patients

Mary Caffrey
Two studies evaluated how well the dual inhibitor reduced glycated hemoglobin (A1C) while measuring instances of hypoglycemia and other safety measures.
<1
...
56789101112>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo